The UK’s BioIndustry Association (BIA) has publishes its 10-year Vision for the UK life science sector called “A Vision for the UK life sciences sector in 2035”, the culmination of 18 months of research and engagement with members and the broader life science ecosystem.
Thanking all involved as he launched the Vision, Steve Bates, chief executive of the BIA, said: “The UK is a global life sciences leader. Yet unlocking UK biotech’s full potential requires a shift in mindset. A lack of commercial ambition, plus lingering suspicion within academia and the National Health Service (NHS) of industry’s profit motive, have contributed to others reaping much of the economic reward from our country’s extraordinary innovations.”
He continued: “The UK needs to grow its biotech companies to boost nationwide economic expansion and health outcomes. We must embrace their commercial success as core to UK growth, rather than shy away from making money in healthcare and net zero.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze